Observed High Adherence to Recombinant Human Growth Hormone Treatment Using a Multi-Component Approach to Improve Adherence in Individuals with Growth Disorders
bookPart
We explored whether a multi-component approach - using a digital health device, the easypod™ auto-injector, the 'MySupport' patient support programme (PSP) and a Patient Activation Measure® (PAM®) - could improve adherence in patients receiving recombinant human growth hormone (r-hGH). A 13-item PAM was used to assess caregiver self-reported knowledge, resulting in two PAM scores for 88 patients at four UK hospitals after an average of 5.6 months. Most patients improved their PAM score by ≥1 level (43%) or maintained it (>-1 and <1; 21%). In parallel, 74% of patients maintained (-5 to +5%) or improved (≥5%) their adherence. Further studies are required to evaluate a multi-component approach to adherence in a larger population and for a longer duration. Chemicals / CAS human growth hormone, 12629-01-5; Human Growth Hormone; Recombinant Proteins.
TNO Identifier
962969
ISBN
978-1-64368-285-3
Publisher
IOS Press
Source title
Studies in Health Technology and Informatics, 32nd Medical Informatics Europe Conference, Challenges of Trustable AI and Added-Value on Health, MIE 2022, 27 May 2022 through 30 May 2022
Editor(s)
Séroussi, B.
Weber, P.
Dhombres, F.
Grouin, C.
Liebe, J.D.
Pelayo, S.
Pinna, A.
Rance, B.
Sacchi, L.
Ugon, A.
Benis, A.
Gallos, P.
Weber, P.
Dhombres, F.
Grouin, C.
Liebe, J.D.
Pelayo, S.
Pinna, A.
Rance, B.
Sacchi, L.
Ugon, A.
Benis, A.
Gallos, P.
Place of publication
Amsterdam
Pages
817-818